




or a pharmaceutically acceptable salt thereof,
wherein:

R_1 is a bond , , ,



wherein X is a halogen and Y is an alkyl group and

wherein  indicates bonding to R_2 at any position
and  indicates bonding to R_2 and the substituent
at any position; and

R_2 is a bond, $-(CY'_2)_n^-$, $-(CY'_2-CY'=CY')_n^-$,


$-(CY'_2-CY'_2-CH=CH)_n^-$, $-(CY'=CY')_n^-$, or $-(CY'_2-\overset{\overset{O}{\parallel}}{C})_n^-$,

wherein Y' is hydrogen or an alkyl group and wherein n
is 1 to 6; and

R_3 is $-Y''$, $-OH$, $-NH_2$, $-N^+(Y'')_3$, $-COOH$, $-COO^-$,
 $-SO_3H$, $-SO_3^-$, $-C-PO_3H_2$ or $-C-PO_3H^-$, wherein Y'' is an
alkyl group.



Fig. 1A


10051367 012202





or a pharmaceutically acceptable salt thereof,

wherein:

each R'_1 is independently a bond,  $\text{CO}_2\text{Y}''$, 



wherein Y'' is an alkyl group, and wherein  indicates bonding to R'_1 at any position and  indicates bonding to R'_1 and the R'_1 phenyl substituent at any position;


each R'_2 is independently a bond, or $-(\text{CH}_2)_n-$ wherein n is 1-4,

each R'_3 is independently $-\text{Y}''$, $-\text{Y}'''$, $-\text{H}$, $-\text{OH}$, $-\text{OY}''$, $-\text{NO}_2$, $-\text{CN}$, $-\text{NH}_2$, $-\text{COOH}$, $-\text{COY}''$, $-\text{COO}^-$, or a heterocyclic group, wherein Y'' is as defined above and Y''' is a primary, secondary, tertiary or quaternary amine.


Fig. 1B.

2022107965001

Fig. 1C



I




II

R₁ through R₈ are, independently, -H, alkyl, 2-hydroxyalkyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid, alkyl ester of carboxylic acid, carboxylic acid, glucuronyl or glyceryl ester of carboxylic acid, 1,2-dihydroxyalkyl, acetyl, vinyl, glycosyl or, taurate, and


β, γ and δ are, independently, -H, acetyl, glyceryl, benzoate, phenylsulfonate, 2-, or 3-, or 4-N-alkyl-pyridyl, nitrophenyl, halophenyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid.

Fig 1D




10051367 "012202"

Fig. 1E




or pharmaceutically acceptable salt thereof
wherein:

R_1 and R_2 are the same and are:




R_3 and R_4 are the same and are:



Y is halogen or $-CO_2X$,

each X is the same or different and is an alkyl and each R_5 is the same or different (preferably the same) and is H or alkyl.

Fig 1 E



or pharmaceutically acceptable salt thereof

wherein:

R_1 and R_3 are, independently:

$-\text{CO}_2\text{C}_{1-4}$ alkyl; or

$-\text{CO}_2(\text{CH}_2)_n\text{CX}_3$, wherein X is halogen and $n = 1$ to 3 ;

R_2 is:

$-\text{H}$

$-\text{C}_{1-4}$ alkyl

$-\text{COOH}$

$-\text{CO}_2\text{C}_{1-4}$ alkyl,

$-\text{CO}_2(\text{CH}_2)_n\text{CX}_3$, wherein X is halogen and $n = 1$ to 3 ,

$-\text{CON}(\text{CH}_3)_2$, or

$-\text{CX}_3$, wherein X is halogen; and

R_4 is:

$-\text{H}$,

$-\text{C}_{1-4}$ alkyl

$-\text{COOH}$,


$-\text{CO}_2\text{C}_{1-4}$ alkyl,

$-\text{CO}_2(\text{CH}_2)_n\text{CX}_3$, wherein X is halogen and $n = 1$ to 3 ,

$-\text{CON}(\text{CH}_3)_2$, or


$-\text{CX}_3$, wherein X is halogen.

Fig 1G



I

or



II,

or pharmaceutically acceptable salt thereof,

wherein

each R is, independently, a C₁-C₈ alkyl group,

and

each P is, independently, an electron withdrawing group or hydrogen.

10536701





Fig. 1H continued




Figure 2A





Figure 2B



Effect of Radiation & AEO 10113 on Mammary Adenocarcinoma




Fig 2C

Tumor Growth Inhibition R3230 AC Mammary Adenocarcinoma in Fisher rats





Figure 4

Tumor growth inhibition (s.q. chambers)

Dose = 6 mg/kg



Tumor Angiogenesis

Dose = 6 mg/kg






Figure 6



Catalytic Antioxidant Metalloporphyrin
[MnTBAP]

10051367.012202

Figure 7



10051367-012202

202210" 49ET500F

Figure 8





Figure 9

A



B





Figure 10



202210-012202

10051367

Figure 11




Figure 12




Figure 13A




Figure 13B




Figure 14




Figure 15




FIGURE 16
2022FO" & SETSOUT

A549 3H-Thymidine uptake at 24 hours




Figure 17









Figure 18

INC-01 Blinded Mucositis Scores



Percentage of Study Days with Ulceration as Indicated by a Score of 3 or Greater

